Lesogaberan

Lesogaberan

Names
IUPAC name ((R)-3-Amino-2-fluoropropyl)phosphinic acid
Other names AZD-3355
Identifiers
CAS Number	344413-67-8 Y=  Y
ChEMBL	ChEMBL448343 N
ChemSpider	23254384 N
IUPHAR/BPS	7705
Jmol 3D model	Interactive image
PubChem	9833984
UNII	4D6Q6HGC7Z Y
InChI InChI=1S/C3H9FNO2P/c4-3(1-5)2-8(6)7/h3,8H,1-2,5H2,(H,6,7)/t3-/m1/s1 N Key: LJNUIEQATDYXJH-GSVOUGTGSA-N N InChI=1/C3H9FNO2P/c4-3(1-5)2-8(6)7/h3,8H,1-2,5H2,(H,6,7)/t3-/m1/s1 Key: LJNUIEQATDYXJH-GSVOUGTGBQ
SMILES O=P([H])(C[C@@H](CN)F)O
Properties
Chemical formula	C3H9FNO2P
Molar mass	141.08 g·mol−1
Vapor pressure	{{{value}}}
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is YN ?)
Infobox references

Lesogaberan (AZD-3355) was an experimental drug candidate developed by AstraZeneca for the treatment of gastroesophageal reflux disease (GERD). As a GABA_B receptor agonist, it has the same mechanism of action as baclofen, but is anticipated to have fewer of the central nervous system side effects that limit the clinical use of baclofen for the treatment of GERD.